Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

Although the PPARγ agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1–10 μM), and this lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Y-C, Hsu, C, Chen, J-Y, Cheng, A-L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Molecular and Cellular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409938/
https://www.ncbi.nlm.nih.gov/pubmed/15467764
http://dx.doi.org/10.1038/sj.bjc.6602200
_version_ 1782155904618070016
author Shen, Y-C
Hsu, C
Chen, J-Y
Cheng, A-L
author_facet Shen, Y-C
Hsu, C
Chen, J-Y
Cheng, A-L
author_sort Shen, Y-C
collection PubMed
description Although the PPARγ agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1–10 μM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no synergistic effect was found between troglitazone and cytotoxic anticancer agents.
format Text
id pubmed-2409938
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24099382009-09-10 Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines Shen, Y-C Hsu, C Chen, J-Y Cheng, A-L Br J Cancer Molecular and Cellular Pathology Although the PPARγ agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1–10 μM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no synergistic effect was found between troglitazone and cytotoxic anticancer agents. Nature Publishing Group 2004-10-18 2004-10-05 /pmc/articles/PMC2409938/ /pubmed/15467764 http://dx.doi.org/10.1038/sj.bjc.6602200 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Shen, Y-C
Hsu, C
Chen, J-Y
Cheng, A-L
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title_full Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title_fullStr Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title_full_unstemmed Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title_short Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
title_sort lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409938/
https://www.ncbi.nlm.nih.gov/pubmed/15467764
http://dx.doi.org/10.1038/sj.bjc.6602200
work_keys_str_mv AT shenyc lackofefficacyoftroglitazoneatclinicallyachievableconcentrationswithorwithout9cisretinoicacidorcytotoxicagentsforhepatocellularcarcinomacelllines
AT hsuc lackofefficacyoftroglitazoneatclinicallyachievableconcentrationswithorwithout9cisretinoicacidorcytotoxicagentsforhepatocellularcarcinomacelllines
AT chenjy lackofefficacyoftroglitazoneatclinicallyachievableconcentrationswithorwithout9cisretinoicacidorcytotoxicagentsforhepatocellularcarcinomacelllines
AT chengal lackofefficacyoftroglitazoneatclinicallyachievableconcentrationswithorwithout9cisretinoicacidorcytotoxicagentsforhepatocellularcarcinomacelllines

Ejemplares similares